Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
featured
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 in 3 people. The drug sirolimus may help by suppressing

anemia
myelodysplastic syndromes
anemia studies
aplastic anemia
myelodysplastic syndrome (mds)
  • 61 views
  • 22 Dec, 2020
  • 1 location
featured
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which suppress the immune system and stop it from

anemia
myelodysplastic syndromes
anemia studies
aplastic anemia
myelodysplastic syndrome (mds)
  • 123 views
  • 22 Dec, 2020
  • 1 location
featured
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells

, participants will have regular doses of cyclosporine and methotrexate to prevent rejection of the donor cells. Participants will have three doses of methotrexate within the week after the transplant, but will

anemia
myelodysplastic syndromes
anemia studies
aplastic anemia
myelodysplastic syndrome (mds)
  • 86 views
  • 22 Dec, 2020
  • 1 location
featured
Opportunity to participate: New Psoriasis Study Being Conducted

Opportunity to participate: New Psoriasis Study Being Conducted

  • 230 views
  • 08 Nov, 2020
  • 1 location
featured
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

  • 248 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

  • 204 views
  • 08 Nov, 2020
  • 1 location
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

This interventional Phase II, single-arm, multicenter, open-label study will investigate the efficacy and safety of a combination regimen of 6 months eltrombopag and cyclosporine treatment in

cyclosporine
platelet count
reticulocyte count
neutrophil count
aplastic anemia
  • 350 views
  • 28 Dec, 2020
  • 23 locations
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the

monoclonal antibodies
metastatic colorectal cancer
panitumumab
irinotecan
tumor growth
  • 129 views
  • 07 Nov, 2020
  • 12 locations
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin before and after transplant may stop this

allogeneic bone marrow transplantation
filgrastim
pegaspargase
cyclophosphamide
cell transplantation
  • 12 views
  • 04 Aug, 2019
  • 5 locations
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

corticosteroids
monoclonal antibodies
immunosuppressive agents
adalimumab
small molecule
  • 103 views
  • 13 Aug, 2020
  • 27 locations